U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H14O5
Molecular Weight 274.2687
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of METHYSTICIN

SMILES

COC1=CC(=O)O[C@H](C1)\C=C\C2=CC=C3OCOC3=C2

InChI

InChIKey=GTEXBOVBADJOQH-FWEMWIAWSA-N
InChI=1S/C15H14O5/c1-17-12-7-11(20-15(16)8-12)4-2-10-3-5-13-14(6-10)19-9-18-13/h2-6,8,11H,7,9H2,1H3/b4-2+/t11-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H14O5
Molecular Weight 274.2687
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Methysticin is a kavalactone originally found in Piper methysticum (kava plant). Methysticin exhibits neuroprotective, neuromodulatory, and antifungal activities. Methysticin may also display anti-inflammatory benefit, inhibiting activation of NF-κB in lung adenocarcinoma tissue. Methysticin activates Nrf2 in neurons and astroglia, protecting against amyloid-β (Aβ)-induced neurotoxicity. This compound displays antimicrobial efficacy against species of Fusarium, Trichoderma, and Colletotrichum. Additionally, methysticin inhibits peak amplitude of voltage-gated Na+ channels in hippocampal neurons. Methysticin administration activates the Nrf2 pathway and reduces neuroinflammation, hippocampal oxidative damage and memory loss in a mouse model of AD. Therefore, kavalactones might be suitable candidates to serve as lead compounds for the development of a new class of neuroprotective drugs.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1.
2011-12
Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.
2005-10
Patents

Sample Use Guides

Mice: Treatment of transgenic APP/Psen1 mice (n=6) was started at an age of 25 weeks and lasted for 27 weeks. The animals were treated once a week with 6 mg/kg bodyweight methysticin.
Route of Administration: Oral
In Vitro Use Guide
In a concentration-range from 10 to 100 uM methysticin reversibly blocked epileptiform activity in in vitro rat seizure models.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:34:30 GMT 2025
Edited
by admin
on Mon Mar 31 19:34:30 GMT 2025
Record UNII
M832AIJ6HX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYSTICIN
MI  
Common Name English
NSC-112158
Preferred Name English
KAVATIN
Common Name English
KAVAHIN
Common Name English
(6R)-6-((1E)-2-(1,3-BENZODIOXOL-5-YL)ETHENYL)-5,6-DIHYDRO-4-METHOXY-2H-PYRAN-2-ONE
Systematic Name English
METHYSTICIN [MI]
Common Name English
6-(3',4'-METHYLENEDIOXYSTYRYL)-4-METHOXY-5,6-DIHYDRO-2H-PYRAN-2-ONE
Common Name English
Classification Tree Code System Code
DSLD 2592 (Number of products:13)
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
Code System Code Type Description
MERCK INDEX
m7484
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID5033674
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
MESH
C076881
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
PUBCHEM
5281567
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
CAS
495-85-2
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
WIKIPEDIA
METHYSTICIN
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
NSC
112158
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
FDA UNII
M832AIJ6HX
Created by admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT